These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 11717598)

  • 1. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial.
    Kini A; Reich D; Marmur JD; Mitre CA; Sharma SK
    Am Heart J; 2001 Dec; 142(6):965-9. PubMed ID: 11717598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high-risk saphenous vein graft lesions: comparison with a historical control group.
    Khan MA; Liu MW; Chio FL; Yates VB; Chapman GD; Misra VK; Sweeney A; Dean LS
    Catheter Cardiovasc Interv; 2001 Jan; 52(1):40-4. PubMed ID: 11146520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices.
    Kini A; Kini S; Marmur JD; Bertea T; Dangas G; Cocke TP; Sharma SK
    Catheter Cardiovasc Interv; 1999 Oct; 48(2):123-9. PubMed ID: 10506764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
    Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ;
    Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque.
    Fujii K; Carlier SG; Mintz GS; Kobayashi Y; Jacoboff D; Nierenberg H; Takebayashi H; Yasuda T; Moussa I; Dangas G; Mehran R; Lansky AJ; Kreps EM; Collins M; Stone GW; Leon MB; Moses JW
    Am J Cardiol; 2005 Feb; 95(3):355-9. PubMed ID: 15670544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Narins CR; Miller DP; Califf RM; Topol EJ
    J Am Coll Cardiol; 1999 Mar; 33(3):647-53. PubMed ID: 10080464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial.
    Bertrand OF; Rodés-Cabau J; Larose E; Nguyen CM; Déry JP; Proulx G; Roy L; Poirier P; Costerousse O; De Larochellière R
    Int J Cardiol; 2009 Aug; 136(2):165-70. PubMed ID: 18656274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.
    Pels K; Schröder J; Witzenbichler B; Müller D; Morguet A; Pauschinger M; Schultheiss HP; Arntz HR
    Eur J Emerg Med; 2008 Dec; 15(6):324-9. PubMed ID: 19078834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study.
    Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP
    Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prehospital abciximab in ST-segment elevation myocardial infarction: results of the randomized, double-blind MISTRAL study.
    Ohlmann P; Reydel P; Jacquemin L; Adnet F; Wolf O; Bartier JC; Weiss A; Lapostolle F; Gaultier C; Salengro E; Benamer H; Guyon P; Chevalier B; Catan S; Ecollan P; Chouihed T; Angioi M; Zupan M; Bronner F; Bareiss P; Steg G; Montalescot G; Monassier JP; Morel O
    Circ Cardiovasc Interv; 2012 Feb; 5(1):69-76, S1. PubMed ID: 22319064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.
    Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Gaudreault V; Proulx G; Barbeau G; Déry JP; Gleeton O; Manh-Nguyen C; Noël B; Roy L; Costerousse O; De Larochellière R;
    Am J Cardiol; 2010 Jun; 105(11):1520-7. PubMed ID: 20494655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
    Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study.
    Tousek P; Rokyta R; Tesarova J; Pudil R; Belohlavek J; Stasek J; Rohac F; Widimsky P
    Acute Card Care; 2011 Sep; 13(3):116-22. PubMed ID: 21526919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
    Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of creatine kinase-MB elevation after percutaneous coronary intervention: results from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
    Lindsey JB; Kennedy KF; Stolker JM; Gilchrist IC; Mukherjee D; Marso SP; Pencina MJ; Kleiman NS; Cohen DJ
    Circ Cardiovasc Interv; 2011 Oct; 4(5):474-80. PubMed ID: 21972402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
    Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L;
    Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries.
    Hausleiter J; Kastrati A; Mehilli J; Schühlen H; Pache J; Dotzer F; Glatthor C; Siebert S; Dirschinger J; Schömig A;
    J Intern Med; 2004 Nov; 256(5):388-97. PubMed ID: 15485474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.